Search results for "Lymphatic"

showing 10 items of 1179 documents

Granulomatous slack skin: report of a case associated with Hodgkin's disease and a review of the literature.

1994

We report a case of granulomatous slack skin (GSS) associated with Hodgkin's disease, and review the literature on this entity. GSS, a variant of cutaneous T-cell lymphoma, clinically presents with erythematous patches in the flexures, which gradually transform into bulky, pendulous areas of skin. Histology shows an elastolytic granulomatous infiltrate, with atypical lymphoid cells, and occasional epidermotropism. As far as we are aware, 10 cases of GSS, including our patient, have been reported in detail. The male:female ratio of these cases is 9:1, and the age range 15-51 years. Five cases were associated with Hodgkin's disease, one with small lymphocytic lymphoma, and one developed cutan…

AdultMalePathologymedicine.medical_specialtyAdolescentmedicine.medical_treatmentDermatologychemistry.chemical_compoundMaintenance therapyhemic and lymphatic diseasesmedicineHumansSkinChemotherapyChlorambucilbusiness.industryGranulomatous slack skinMiddle Agedmedicine.diseaseHodgkin DiseaseNitrogen mustardPeripheral T-cell lymphomaLymphomaLymphoma T-Cell CutaneousRadiation therapychemistrybusinessmedicine.drugThe British journal of dermatology
researchProduct

Morphometric Study of the Bone Marrow in Polycythemia Vera Following Interferon-Alpha Therapy

1993

Bone marrow cellularity and extent of fibrotic change were determined in nineteen patients with polycythemia vera, treated with interferon-alpha (IFN) for 1 year. The cellularity was evaluated with an interactive semiautomatic method using Leitz TAS plus microscope: in particular, number and size of megakaryocytes were evaluated after immunostaining with Y2/51 (CD 61); reticulin content was studied by light microscope with a semiquantitative method. Before IFN therapy mean cellularity was 80.5% (+/- 13.7). After 6 and 12 months mean cellularity was 75.4% and 68.4% respectively. Six months after cessation of IFN therapy the cellularity was 69.1%. A decrease of the number, density and morphom…

AdultMalePathologymedicine.medical_specialtyAlpha interferonCell CountPathology and Forensic MedicinePolycythemia veraBone MarrowFibrosishemic and lymphatic diseasesmedicineHumansMyelofibrosisPolycythemia VeraAgedAged 80 and overbusiness.industryInterferon-alphaCell BiologyMiddle Agedmedicine.diseaseBone marrow cellularitymedicine.anatomical_structurePrimary MyelofibrosisMarrow fibrosisFemaleBone marrowbusinessMegakaryocytesImmunostainingPathology - Research and Practice
researchProduct

ADC measurements in diffuse large B-cell lymphoma and follicular lymphoma: a DWI and cellularity study.

2012

Diffusion-weighted magnetic resonance imaging (DW-MRI) allows quantifying the random motion of water molecules in tissue by means of apparent diffusion coefficient (ADC) measurements. The aim of the study was to determine whether ADC measurements allow discrimination of diffuse large B-cell lymphoma (DLBCL) from follicular lymphoma (FL), and to examine the relationship between cellularity and ADC value of the tumor using DWI.Thirty-two patients with histologically proven non-Hodgkin lymphoma (21 with DLBCL and 11 with FL, 17 males and 15 females, mean age 62±13 years) underwent conventional MRI and DWI examination before treatment. The ADC values of DLBCL were compared to those of FL. The A…

AdultMalePathologymedicine.medical_specialtyBiopsyFollicular lymphomaContrast MediaMeglumineimmune system diseaseshemic and lymphatic diseasesBiopsymedicineOrganometallic CompoundsEffective diffusion coefficientHumansRadiology Nuclear Medicine and imagingIn patientProspective StudiesAgedAged 80 and overMegluminemedicine.diagnostic_testbusiness.industryta1182Magnetic resonance imagingGeneral MedicineMiddle Agedta3122medicine.diseaseLymphomabody regionsDiffusion Magnetic Resonance ImagingFemaleLymphoma Large B-Cell DiffuseNuclear medicinebusinessDiffuse large B-cell lymphomamedicine.drugEuropean journal of radiology
researchProduct

MYD88 L265P mutation and interleukin‐10 detection in cerebrospinal fluid are highly specific discriminating markers in patients with primary central …

2021

Reliable biomarkers are needed to avoid diagnostic delay and its devastating effects in patients with primary central nervous system (CNS) lymphoma (PCNSL). We analysed the discriminating sensitivity and specificity of myeloid differentiation primary response (88) (MYD88) L265P mutation (mut-MYD88) and interleukin-10 (IL-10) in cerebrospinal fluid (CSF) of both patients with newly diagnosed (n = 36) and relapsed (n = 27) PCNSL and 162 controls (118 CNS disorders and 44 extra-CNS lymphomas). The concordance of MYD88 mutational status between tumour tissue and CSF sample and the source of ILs in PCNSL tissues were also investigated. Mut-MYD88 was assessed by TaqMan-based polymerase chain reac…

AdultMalePathologymedicine.medical_specialtyLymphomaBiopsyConcordanceinterleukin-10diffuse large B-cell lymphomaMutation MissenseCentral Nervous System Neoplasms03 medical and health sciencesprimary CNS lymphoma0302 clinical medicineCerebrospinal fluidhemic and lymphatic diseasesBiopsyBiomarkers TumorTaqManmedicineHumansdiffuse large B-cell lymphoma interleukin-10 interleukin-6 MYD88 L265P mutation primary CNS lymphomaProspective cohort studyAgedmedicine.diagnostic_testbusiness.industryinterleukin-6Primary central nervous system lymphomaHematologyMiddle Agedmedicine.diseaseInterleukin-10Neoplasm ProteinsLymphomaMYD88 L265P mutationAmino Acid Substitution030220 oncology & carcinogenesisMyeloid Differentiation Factor 88FemalebusinessDiffuse large B-cell lymphoma030215 immunologyBritish Journal of Haematology
researchProduct

CXCR3 chemokine receptor immunoreactivity in primary cutaneous malignant melanoma: correlation with clinicopathological prognostic factors.

2007

A role for CXCR3, the receptor for chemokines Mig, IP-10 and interferon-inducible T cell alpha-chemoattractant, in tumour cell migration during melanoma progression has been proposed.To analyse CXCR3 expression in primary cutaneous malignant melanomas and its comparison with clinicopathological and prognostic factors.A retrospective immunohistochemical study was carried out on formalin-fixed paraffin-wax-embedded sections from 82 patients with primary invasive cutaneous melanomas, with a monoclonal antibody to CXCR3 (clone 49801.111; RD Systems). Immunoreactivity was semiquantitatively evaluated: labelling intensity (0, absent; 1, weak; 2, moderate; 3, strong) multiplied by the percentage o…

AdultMalePathologymedicine.medical_specialtyReceptors CXCR3Skin NeoplasmsCXCR3Pathology and Forensic MedicineImmunoenzyme TechniquesmedicineBiomarkers TumorHumansNeoplasm InvasivenessLymph nodeMelanomaAgedRetrospective StudiesAged 80 and overUnivariate analysisbusiness.industryMelanomaGeneral MedicineMiddle Agedmedicine.diseasePrognosisSurvival AnalysisNeoplasm Proteinsmedicine.anatomical_structureLymphatic MetastasisCutaneous melanomaDisease ProgressionImmunohistochemistryFemaleReceptors ChemokineOriginal ArticleSkin cancerbusinessImmunostainingJournal of clinical pathology
researchProduct

Efficacy and safety during formulation switch of a pasteurized VWF/FVIII concentrate: results from an Italian prospective observational study in pati…

2012

Summary Von Willebrand disease (VWD) is an inherited bleeding disorder caused by the quantitative or qualitative deficiency of von Willebrand factor (VWF). Replacement therapy with plasma-derived VWF/factor VIII (FVIII) concentrates is required in patients unresponsive to desmopressin. To assess the efficacy, safety and ease of use of a new, volume-reduced (VR) formulation of VWF/FVIII concentrate Haemate® P in patients requiring treatment for bleeding or prophylaxis for recurrent bleeding or for invasive procedures. Pharmacoeconomic variables were also recorded. Data were analysed using descriptive statistics. This was a multicentre, prospective, observational study. Consecutively enrolled…

AdultMalePediatricsmedicine.medical_specialtyAdolescentBlood Loss SurgicalSevere diseaseHemorrhageSettore MED/15 - Malattie Del SangueYoung AdultVon Willebrand factorCost of Illnesshemic and lymphatic diseaseshemophiliavon Willebrand FactorVon Willebrand diseasemedicineHumansIn patientProspective StudiesDesmopressinAdverse effectChildGenetics (clinical)AgedFactor VIIIbiologybusiness.industryDrug SubstitutionAnticoagulantsHematologyGeneral MedicineMiddle Agedmedicine.diseaseResponse to treatmentHospitalizationvon Willebrand DiseasesItalyChild Preschoolbiology.proteinPasteurizationObservational studyFemalebusinessmedicine.drug
researchProduct

AML transformation in 56 patients with Ph- MPD in two well defined populations.

2009

The Philadelphia chromosome-negative (Ph-) chronic myeloproliferative disorders (MPD) have an inherent tendency for transformation into acute myelogenous leukaemia (AML). The long-term rate of leukaemic transformation in unselected MPD patients was studied in well-defined MPD populations in Gothenburg, Sweden and the Cote d'Or area, Burgundy, France, respectively. Over a median observation time of 15 yr, 56 subjects (7%) out of a total of 795 patients with Ph- MPD transformed to AML. The yearly incidence of AML transformation was 0.38% in polycythaemia vera (PV), 0.37% in essential thrombocythaemia (ET) and 1.09% in idiopathic myelofibrosis (IMF). The incidence of AML development was signif…

AdultMalePediatricsmedicine.medical_specialtyPolycythaemiaMyeloidIdiopathic myelofibrosisGastroenterologyLeukemia Myeloid Chronic Atypical BCR-ABL Negativehemic and lymphatic diseasesInternal medicineMedicineHumansSurvival analysisAgedAged 80 and overMyeloproliferative Disordersbusiness.industryIncidence (epidemiology)HematologyGeneral MedicineMiddle Agedmedicine.diseaseSurvival AnalysisChronic myeloproliferative disordersLeukemiamedicine.anatomical_structureFemalebusinessMale predominanceEuropean journal of haematology
researchProduct

Reproducibility of the WHO histological criteria for the diagnosis of Philadelphia chromosome-negative myeloproliferative neoplasms

2014

This study, performed on behalf of the Italian Registry of Thrombocythaemias (Registro Italiano Trombocitemie), aimed to test the inter-observer reproducibility of the histological parameters proposed by the WHO classification for the diagnosis of the Philadelphia chromosome-negative myeloproliferative neoplasms. A series of 103 bone marrow biopsy samples of Philadelphia chromosome-negative myeloproliferative neoplasms consecutively collected in 2004 were classified according to the WHO criteria as follows: essential thrombocythaemia (n=34), primary myelofibrosis (n=44) and polycythaemia vera (n=25). Two independent groups of pathologists reviewed the bone marrow biopsies. The first group w…

AdultMalePolycythaemiaPathologymedicine.medical_specialtymyeloproliferative neoplasmPhiladelphia Chromosome Negativeessential thrombocythaemiaWorld Health Organizationpolycythaemia veramyeloproliferative neoplasmsPathology and Forensic MedicineYoung AdultCohen's kappaBone Marrowhemic and lymphatic diseasesBiopsyHumansMedicinePhiladelphia ChromosomeMyelofibrosisPolycythemia VeraAgedAged 80 and overObserver VariationWHO classificationmedicine.diagnostic_testbusiness.industryprimary myelofibrosiReproducibility of ResultsMiddle Agedmedicine.diseaseprimary myelofibrosisFemaleWho criteriaDifferential diagnosisessential thrombocythaemia; myeloproliferative neoplasms; primary myelofibrosis; polycythaemia vera; WHO classificationbusinessWho classificationThrombocythemia EssentialModern Pathology
researchProduct

Molecular analysis of the erythropoietin receptor system in patients with polycythaemia vera

1994

Summary Erythropoietin (EPO) is a potent regulator of the viability, proliferation and differentiation of erythroid progenitor cells. Its effect is mediated by binding to the erythropoietin receptor (EPO-R), a member of a new cytokine receptor family. Alterations of the EPO/EPO-R system have recently been shown to be involved in the pathogenesis of familial erythrocytosis and polycythaemia vera (PV). In order to define whether genetic changes in the EPO-R gene and its ligand play a role in the development of PV, the structure and expression levels of the EPO-R and EPO genes were examined in samples from bone marrow and/or peripheral blood mononuclear cells of 24 patients with PV. As expecte…

AdultMalePolycythaemiaTranscription GeneticMolecular Sequence DataBiologyPolymerase Chain ReactionPeripheral blood mononuclear cellPolycythemia veraBone Marrowhemic and lymphatic diseasesReceptors ErythropoietinmedicineHumansRNA MessengerErythropoietinPolycythemia VeraPolymorphism Single-Stranded ConformationalAgedBase SequenceHematologyMiddle Agedmedicine.diseaseMolecular biologyReverse transcriptaseErythropoietin receptormedicine.anatomical_structureErythropoietinFemaleBone marrowOligonucleotide ProbesCytokine receptormedicine.drugBritish Journal of Haematology
researchProduct

Leucocytosis and thrombosis at diagnosis are associated with poor survival in polycythaemia vera: a population-based study of 327 patients

2012

Three hundred and twenty-seven patients from two population-based cohorts with an established diagnosis of polycythaemia vera were studied for prognostic risk factors for survival and leukaemia in a long-term survey. The relative survival (RS) was 72% and 46% at 10 and 20 years respectively, from the time of diagnosis. Multivariate analysis identified age >70 years, white blood cell count >13 × 10(9) /l and thrombo-embolism at diagnosis as independent risk factors. Patients with two or three of these factors had a 10 year RS of 26%, compared with 59% and 84% in patients with one and no risk factors, respectively. Age and leucocyte count are the main predicting factors for survival in polycy…

AdultMalePolycythaemiamedicine.medical_specialtyLeukocytosisPopulationComorbidityKaplan-Meier EstimateLeukocyte CountYoung AdultPolycythemia veraRisk FactorsCause of DeathNeoplasmshemic and lymphatic diseasesWhite blood cellInternal medicineEpidemiologymedicineHumansRisk factoreducationPolycythemia VeraAgedProportional Hazards ModelsAged 80 and overHeart FailureSwedeneducation.field_of_studyRelative survivalProportional hazards modelbusiness.industryThrombosisHematologyMiddle AgedPrognosismedicine.diseaseSurgeryLeukemia Myeloid Acutemedicine.anatomical_structureDisease ProgressionFemaleFrancebusinessFollow-Up StudiesBritish Journal of Haematology
researchProduct